drugset
drugset / Trial / NCT03004209

Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

NCT03004209 ↗

Phase 4 Withdrawn Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.

Timeline

Start
2016-12
Primary completion
2018-02-06
Completion
2018-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 100 iu/kg —

Indications

autoimmune encephalitis